Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company, reported its second-quarter 2026 financial and operational results, underscoring significant progress in its AI-driven oncology pipeline and the strategic establishment of Open Medicine AI (OMAI) as a separate entity. The company highlighted emerging data from its Phase 2 HARMONIC trial, regulatory clearances for its lead candidates, and a notable reduction in operating losses.
In the HARMONIC trial, LP-300, a cisplatin/ethacraplatin analog, demonstrated a deepening progression-free survival benefit with longer treatment duration in patients with EGFR exon 21 L858R mutations, a population with high unmet need. The FDA reviewed key protocol amendments without objection, allowing the trial to proceed as planned. Additionally, the European Medicines Agency cleared an investigator-initiated Phase 1b/2 trial of LP-184, also known as zirdafulven, in biomarker-selected advanced bladder cancer. The U.S. Patent and Trademark Office issued a Notice of Allowance for a three-gene patient-selection signature for LP-184, strengthening the company's intellectual property portfolio.
In August, Lantern established Open Medicine AI as a wholly owned subsidiary and entered into board-approved commercial licensing agreements for its multi-agentic AI co-scientist platform, previously launched as withZeta.ai. This move positions OMAI to independently monetize the platform, which is now available as a subscription-based research tool for the global biomedical community. The spin-off is expected to create new revenue streams and enhance focus on AI-driven drug discovery.
Financially, Lantern reported a second-quarter loss from operations of approximately $3.5 million, a 25% improvement from the $4.7 million loss in the same period last year. Research and development expenses declined 42% to roughly $1.8 million, reflecting disciplined cost management. Net loss was approximately $7.1 million, or $0.57 per share, compared with $4.3 million, or $0.40 per share, a year earlier. The increase was largely due to approximately $3.6 million in warrant-related expenses. As of June 30, 2026, cash, cash equivalents, and marketable securities totaled approximately $7.4 million.
These developments are critical as they demonstrate Lantern's ability to advance its pipeline while reducing operational burn, a key consideration for clinical-stage biotech investors. The regulatory progress for LP-300 and LP-184, combined with the innovative OMAI spin-off, could position the company for value creation. The company's AI-driven approach, leveraging its proprietary RADR platform, aims to improve the efficiency and success rates of cancer drug development.
For more details, the full press release is available at https://nnw.fm/m9pULA. Lantern Pharma continues to focus on transforming cancer therapies through AI and precision medicine, with its headquarters in Dallas, Texas, and an AI Center of Excellence in Bengaluru, India.
